Decision Curve Analysis (DCA) has emerged as a valuable method for evaluating predictive models, yet its application in research—particularly pediatrics—remains limited. This article serves as a didactic tutorial, providing an applied introduction to DCA and clarifying key concepts that often generate confusion. The advantages of DCA over traditional metrics such as the area under the ROC curve (AUC) are highlighted through a simulated cohort of pediatric patients with suspected appendicitis. Three predictors were compared: a composite clinical score (Pediatric Appendicitis Score, PAS), leukocyte count, and serum sodium. While both PAS and leukocyte count achieved acceptable AUCs, the decision curves revealed substantially different net benefit profiles, demonstrating that a higher AUC does not necessarily translate into superior clinical utility. In contrast, serum sodium, with poor discrimination, consistently failed to provide meaningful benefit across thresholds. Common methodological pitfalls—including overfitting, calibration, and the limitations of dichotomous predictors—are also discussed. By contrasting a strong predictor, a moderate predictor, and a weak biomarker, this tutorial underscores the unique contribution of DCA as a practical framework for moving beyond statistical performance toward clinically meaningful decision support.

The authors have declared no competing interest.

There is no external funding to declare.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Conflict of interest: There is no conflict of interest or external funding to declare. The author does not have anything to disclose

Informed consent: N/A

AI Use Disclosure: Artificial intelligence (ChatGPT 4, OpenAI) was used for language editing and for generating a synthetic dataset under the author’s explicit instructions. It did not influence the scientific content, analysis, or interpretation.

Data Availability Statement: The dataset used in this study is simulated and has been provided as supplementary material (Supplementary File 1).

Ethical Statement: This study did not involve human subjects or animals. As only simulated data were used, no ethical approval or informed consent was required.

CRediT author statement: Javier Arredondo Montero (JAM): Conceptualization; Methodology; Software; Validation; Formal analysis; Investigation; Resources; Data Curation; Writing – Original Draft; Writing – Review & Editing; Visualization; Supervision; Project administration.

The dataset used in this study is simulated and has been provided as supplementary material (Supplementary File 1).